Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 4 (2007), Issue 9 (September)

1. Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate.
   Blood, 110(6): 2049-56. [Abstract] [Full-text]
2. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
   J Nucl Med, 48(9): 1501-10. [Abstract] [Full-text]
3. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy.
   Clin Cancer Res, 13(17): 5133-43. [Abstract] [Full-text]
4. Long Term Disease-Free Survival and T Cell and Antibody Responses in Women with High-Risk HER2+ Breast Cancer Following Vaccination Against HER2+
   J Transl Med, 5(1): 42. [Abstract] [Full-text]
5. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience.
   Cancer, 110(6): 1195-200. [Abstract] [Full-text]
6. Cardiovascular effects of breast cancer radiotherapy.
   Cancer Treat Rev, 33(6): 578-93. [Abstract] [Full-text]
7. Bilateral synchronous breast carcinomas followed by a metastasis to the gallbladder: a case report.
   World J Surg Oncol, 5(1): 101. [Abstract] [Full-text]
8. Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging.
   J Med Chem, 50(19): 4759-65. [Abstract] [Full-text]
9. The emerging role of pharmacogenomics in biologics.
   Clin Pharmacol Ther, 82(4): 466-71. [Abstract] [Full-text]
10. Beyond genomics.
    Clin Pharmacol Ther, 82(4): 366-70. [Abstract] [Full-text]
11. (111)Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.
    Eur J Cancer, 43(14): 2046-51. [Abstract] [Full-text]
12. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.
    Int J Radiat Oncol Biol Phys, 69(2): 572-9. [Abstract] [Full-text]
13. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
    Arch Surg, 142(9): 855-61; discussion 860-1. [Abstract] [Full-text]
14. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
    Cancer, 110(5): 965-72. [Abstract] [Full-text]
15. Mechanisms of HER2-induced endothelial cell retraction.
    Ann Surg Oncol, 14(10): 2971-8. [Abstract] [Full-text]
16. Lapatinib in the treatment of breast cancer.
    Expert Rev Anticancer Ther, 7(9): 1183-92. [Abstract] [Full-text]
17. Trastuzumab not for ductal carcinoma in situ?
    Anticancer Drugs, 18(10): 1231-5. [Abstract] [Full-text]
18. HER2 targeted therapy in breast cancer...beyond Herceptin.
    Rev Endocr Metab Disord. [Abstract] [Full-text]
19. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
    Breast Cancer Res Treat, 105(3): 319-26. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.